All In Biotech

Drug Trial Radar · NCT07412496

A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy

A Randomized, Vehicle-Controlled, Double-Masked, Parallel-Group Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Mar 31, 2026

Primary completion

Oct 4, 2026

Study completion Oct 4, 2026

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 58 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-masked study to evaluate the use of Topical Ocular BL1332 for the management of post-operative pain after Photorefractive Keratectomy (PRK) surgery.

Conditions

  • Pain, Postoperative

Interventions

  • Topical Ocular BL1332 low doseDrug

    Administered 5 times a day

  • Topical Ocular BL1332 high doseDrug

    Administered 5 times a day

  • BL1332 Vehicle ophthalmic vehicleDrug

    Administered 5 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular pain intensity following PRK surgeryTime frame: Assessed at a 24-hour period following PRK surgery

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site 14

    Scottsdale, Arizona

  • Site 3

    Long Beach, California

  • Site 10

    Pasadena, California

  • Site 11

    San Diego, California

  • Site 15

    Davie, Florida

  • Site 13

    Brookline, Massachusetts

  • Site 5

    Bloomington, Minnesota

  • Site 8

    Amherst, New York

  • Site 9

    Fargo, North Dakota

  • Site 6

    West Fargo, North Dakota

  • Site 1

    Sioux Falls, South Dakota

  • Site 2

    Cedar Park, Texas

  • Site 12

    Draper, Utah

  • Site 4

    Salt Lake City, Utah

  • Site 7

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.